ArticleDiscover oncology2025
An exploratory study on the potential of angiogenic genes in early HNSCC detection.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early diagnosis and prognosis of head and neck tumors are crucial for enhancing patients’ quality of life. This study focuses on angiogenic genes to develop prognostic and diagnostic models, offering a novel strategy to improve patient outcomes and increase the early diagnosis rate of HNSCC.
methodsSamples were clustered based on MSI, SCNA, and mTMB. A vascularization-related diagnostic and prognostic scoring model was constructed through the analysis of differentially expressed genes (DEGs). The model was validated using univariate and multivariate Cox proportional hazards analyses with data from the International Cancer Genome Consortium (ICGC). Subsequently, samples were grouped according to model scores, and immune infiltration analysis was conducted. Immune profiling, combined with narrow band imaging (NBI), was employed to verify the diagnostic model.
resultsCluster analysis based on MSI, SCNA, and mTMB burden values effectively stratified HNSCC into three distinct types. An angiogenesis-related prognostic model was developed from differential gene analysis to assess patient outcomes. Validation using an external database (ICGC dataset) confirmed the model’s robust performance. Following the stratification of TCGA samples into high-risk and low-risk groups based on risk scores, significant differences were observed in expression data and immune cell infiltration between the two cohorts. Furthermore, after adjustments using both univariate and multivariate Cox regression analyses, the risk score index emerged as an independent prognostic factor. Subsequent validation using Narrow Band Imaging (NBI) combined with immunohistochemistry confirmed the model’s utility in diagnosing early-stage head and neck tumors.
conclusionThe model holds potential for application in the diagnostic and prognostic evaluation of early-stage head and neck tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.